Labcorp Holdings Inc. $LH Shares Acquired by Northwestern Mutual Wealth Management Co.

Northwestern Mutual Wealth Management Co. increased its position in Labcorp Holdings Inc. (NYSE:LH) by 113.6% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 8,413 shares of the medical research company’s stock after acquiring an additional 4,475 shares during the period. Northwestern Mutual Wealth Management Co.’s holdings in Labcorp were worth $2,111,000 at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of the company. Bessemer Group Inc. increased its stake in Labcorp by 114.6% during the 4th quarter. Bessemer Group Inc. now owns 393,189 shares of the medical research company’s stock valued at $98,644,000 after buying an additional 209,947 shares during the period. Thrivent Financial for Lutherans increased its stake in Labcorp by 2.5% during the 4th quarter. Thrivent Financial for Lutherans now owns 577,027 shares of the medical research company’s stock valued at $144,765,000 after buying an additional 14,021 shares during the period. Meridian Financial Partners LLC increased its stake in Labcorp by 1.1% during the 4th quarter. Meridian Financial Partners LLC now owns 5,594 shares of the medical research company’s stock valued at $1,505,000 after buying an additional 62 shares during the period. Pinnacle Associates Ltd. increased its stake in Labcorp by 3.9% during the 4th quarter. Pinnacle Associates Ltd. now owns 1,126 shares of the medical research company’s stock valued at $282,000 after buying an additional 42 shares during the period. Finally, Allworth Financial LP increased its stake in Labcorp by 11.9% during the 4th quarter. Allworth Financial LP now owns 6,467 shares of the medical research company’s stock valued at $1,622,000 after buying an additional 688 shares during the period. Institutional investors and hedge funds own 95.94% of the company’s stock.

Insider Activity at Labcorp

In other news, EVP Der Vaart Sandra D. Van sold 548 shares of Labcorp stock in a transaction that occurred on Friday, February 27th. The shares were sold at an average price of $284.91, for a total value of $156,130.68. Following the transaction, the executive vice president owned 2,579 shares of the company’s stock, valued at $734,782.89. The trade was a 17.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Adam H. Schechter sold 8,705 shares of Labcorp stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total transaction of $2,437,051.80. Following the completion of the transaction, the chief executive officer directly owned 80,773 shares in the company, valued at $22,613,209.08. This represents a 9.73% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 15,156 shares of company stock worth $4,095,496 in the last ninety days. Corporate insiders own 0.84% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have commented on the stock. Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a research note on Tuesday, February 17th. Wall Street Zen raised shares of Labcorp from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Robert W. Baird set a $334.00 target price on shares of Labcorp in a research note on Friday, May 1st. Weiss Ratings reissued a “buy (b-)” rating on shares of Labcorp in a research note on Friday, May 8th. Finally, Evercore reissued an “outperform” rating and set a $300.00 target price on shares of Labcorp in a research note on Wednesday, April 8th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $308.00.

Labcorp Stock Performance

Shares of LH opened at $258.91 on Wednesday. The firm’s 50 day moving average is $263.65 and its 200-day moving average is $265.72. The stock has a market capitalization of $21.23 billion, a P/E ratio of 22.93, a P/E/G ratio of 1.82 and a beta of 0.91. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.73 and a quick ratio of 1.54. Labcorp Holdings Inc. has a 12-month low of $241.81 and a 12-month high of $293.72.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $4.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.09 by $0.16. The company had revenue of $3.54 billion for the quarter, compared to analysts’ expectations of $3.51 billion. Labcorp had a net margin of 6.66% and a return on equity of 16.29%. The business’s revenue was up 5.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.84 EPS. Labcorp has set its FY 2026 guidance at 17.700-18.350 EPS. Equities research analysts anticipate that Labcorp Holdings Inc. will post 17.99 EPS for the current fiscal year.

Labcorp Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 11th. Stockholders of record on Friday, May 29th will be paid a $0.72 dividend. The ex-dividend date of this dividend is Friday, May 29th. This represents a $2.88 annualized dividend and a dividend yield of 1.1%. Labcorp’s payout ratio is currently 25.51%.

Labcorp Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.